Mr. Ivan Miliovski reports
VODIS ENTERS CONFIRMATION OF READINESS STAGE
Vodis Pharmaceuticals Inc. has entered the confirmation of
readiness stage to become a licenced producer under the Access to Cannabis for Medical Purposes
Regulations (ACMPR) at its Delta, B.C., facility. The confirmation of readiness stage is the final stage
before obtaining a licence from Health Canada to cultivate cannabis under the ACMPR.
As previously announced, Vodis undertook upgrades to its Delta facility. These upgrades included the
installation of specialized wall finishes in the production and processing areas, upgraded ceramic metal
halide and LED lighting, installation of Ample Organics software for seed-to-sale tracking, and upgrades
to the internal physical security of the facility. The company is completing these upgrades and plans to file
a comprehensive confirmation of readiness evidence package with Health Canada in the coming weeks.
Vodis's chief executive officer, Ivan Miliovski, states: "This is an important milestone that gets us closer to obtaining a
cultivation licence at our Delta facility. We are very excited about the path forward and creating the
shareholder value that we set out to achieve."
The passing of the Cannabis Act has dramatically expanded the Canadian cannabis market. While Vodis
intends to sell into the various provincial recreational markets, the company remains committed to the many
Canadians that have expressed interest in purchasing high-quality Vodis product for medical purposes. The
company encourages future patients to join its e-mail mailing list at its website. The company is also
continuing its brand and future patient outreach efforts at the Grow Up Cannabis Conference and Expo in
Niagara Falls, Ont., on Sept. 7 to Sept. 8, 2018.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America's foremost brand names in the medical and recreational marijuana business
with operations in both the United States and Canada. Its master grow teams have consistently won or placed
at each Canadian competition they have entered with their VIP brand. The company, with facilities in
British Columbia and Washington State, is also actively looking into expansion opportunities in other
countries and throughout the United States.
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of
production, processing or retail activities in the United States, it can license its brand, production and
consulting services to approved Washington State licence holders to ensure that all products produced under
the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.